GLAXO
Glaxosmithkline Pharmaceuticals Limited
Each stock's 10,000-path forecast, rendered as light.
Glaxosmithkline Pharmaceuticals Limited (GLAXO) Stock Analysis & Case Study
Is GLAXO a good buy? The data-driven verdict.
Glaxosmithkline Pharmaceuticals Limited (GLAXO) trades at ₹2,600,on the numbers it worth a closer look, a Downstox Snapshot Score of 56/100.
On the numbers, Glaxosmithkline Pharmaceuticals Limited (GLAXO) worth a closer look, a Downstox Snapshot Score of 56/100, weighing expensive at 41.8× earnings, ROE of 45.6%, a 55% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
GLAXO fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How GLAXO ranks against the 2,373 companies in our screener
- GLAXO's market cap of 44,040 Cr ranks in the 91st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GLAXO's book value of ₹134 ranks in the 61st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GLAXO's promoter holding of 75.0% ranks in the top 5% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GLAXO's 3-year profit (PAT) growth of 18.0% ranks in the 54th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GLAXO's 3-year revenue growth of 6.0% ranks in the 38th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GLAXO's debt-to-equity ratio of 0.01x is lower than 98% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is GLAXO overvalued? GLAXO P/E vs peers
GLAXO trades at 41.8× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
GLAXO share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of GLAXO history (5%/yr drift, 34%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| GLAXO 2027 | ₹1,751 | ₹2,703 | ₹4,172 | +4% |
| GLAXO 2028 | ₹1,517 | ₹2,810 | ₹5,203 | +8% |
| GLAXO 2029 | ₹1,383 | ₹2,921 | ₹6,172 | +12% |
| GLAXO 2030 | ₹1,282 | ₹3,037 | ₹7,193 | +17% |
| GLAXO 2031 | ₹1,191 | ₹3,157 | ₹8,368 | +21% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability GLAXO goes up, or doubles?
The bull case for GLAXO
- GLAXO's return on equity of 45.6% ranks in the top 2% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GLAXO's return on capital employed of 61.4% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- GLAXO's dividend yield of 2.2% ranks in the 89th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹6,172.
The bear case & risks
- GLAXO's P/E of 41.8x is lower than 32% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 19.4× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹1,383.
GLAXO volatility & expected range, how bumpy is the ride?
Over the last 9.8 years GLAXO compounded at 5%/year with annualized volatility of 34%. That volatility implies a 1-year 80% range of ₹1,751-₹4,172, the honest backbone behind any single price target.
GLAXO price forecast, the full 60-month probability fan
GLAXO price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds GLAXO hits common targets within the simulated horizon?
Full multi-horizon detail on the GLAXO price target & forecast page.
GLAXO Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. GLAXO scores 6/8, mixed financial health.
GLAXO MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy GLAXO with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 29.26% | 3.4× |
| ZerodhaCHEAPEST | 29.24% | 3.4× |
| Groww | 29.30% | 3.4× |
| Dhan | 30.00% | 3.3× |
| Kotak Neo | 30.03% | 3.3× |
| Paytm Money | 29.37% | 3.4× |
| Pocketful | 29.39% | 3.4× |
| Fyers | 30.30% | 3.3× |
| Anand RathiCHEAPEST | 29.24% | 3.4× |
| Bajaj Broking | 33.00% | 3.0× |
| Share India | 29.27% | 3.4× |
Compare every broker on the GLAXO MTF page.
About Glaxosmithkline Pharmaceuticals Limited: sector, index & market-cap context
Glaxosmithkline Pharmaceuticals Limited (GLAXO) is a mid-cap NSE-listed company, and a constituent of the Nifty 500 index, with a market capitalisation of ₹44,040 Cr. See more stocks on our screener.
How the GLAXO Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Glaxosmithkline Pharmaceuticals Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
GLAXO analysis, FAQs
Is Glaxosmithkline Pharmaceuticals Limited (GLAXO) a good buy?
On the numbers, Glaxosmithkline Pharmaceuticals Limited (GLAXO) worth a closer look, a Downstox Snapshot Score of 56/100, weighing expensive at 41.8× earnings, ROE of 45.6%, a 55% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is GLAXO overvalued or undervalued?
GLAXO trades at 41.8× earnings, expensive versus the ~22× long-run Nifty average.
What is the GLAXO share price target for 2031?
GLAXO's probability-weighted 2031 median target is ₹3,157, with an 80% range of ₹1,191-₹8,368 (10,000-path Monte-Carlo).
What is the probability GLAXO doubles in 5 years?
The modelled probability of GLAXO reaching ₹5,199 (2×) within 5 years is 26%.
What is the bull case for GLAXO?
GLAXO's return on equity of 45.6% ranks in the top 2% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. GLAXO's return on capital employed of 61.4% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. GLAXO's dividend yield of 2.2% ranks in the 89th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in GLAXO?
GLAXO's P/E of 41.8x is lower than 32% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 19.4× price-to-book means most of the value is intangible/expectations, not assets on the books.